title: [Studies of WBN/Kob rat, 18th report: effect of 1 alpha-OH-D3 on diabetic osteopenia].
abstract: We examined the effect of 1 alpha-OH-D3 on diabetic osteopenia in spontaneously-developed diabetic WBN/Kob rats. Diabetic male WBN/Kob rats aged 12 to 15 months were randomly divided into 1 alpha-OH-D3-treated group (n = 6) and control group (n = 5). 1 alpha-OH-D3 was administered 3 times a week at an oral dose of 0.1 microgram/kg and triglyceride was administered in the control group during the observation period of 12 weeks. Although plasma Ca level decreased significantly in the vehicle-treated group, there was no significant change in plasma Ca level in the 1 alpha-OH-D3-treated group. Urinary Ca excretion significantly increased in the 1 alpha-OH-D3-treated group compared with that in the vehicle-treated group. As for plasma vitamin D metabolites levels after the 12 week-treatment, although there was no significant difference in plasma 25-OH-D and 24,25(OH)2D levels, plasma 1,25(OH)2D level was significantly increased in the 1 alpha-OH-D3-treated group compared with that in the vehicle-treated group. There was no significant difference in plasma bone-Gla protein level between 1 alpha-OH-D3-treated and vehicle-treated groups. As for bone mineral content (BMC) in the femur measured by a dual energy absorptiometer, BMC was significantly increased in the 1 alpha-OH-D3-treated group compared with than in the vehicle-treated group. In conclusion, 1 alpha-OH-D3 ameliorated diabetic osteopenia in WBN/Kob rats through the normalization of vitamin D metabolism.
authors.affiliation: Third Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: J
authors.initials: J
authors.lastname: Yokoyama
authors.forename: M
authors.initials: M
authors.lastname: Nemoto
authors.forename: M
authors.initials: M
authors.lastname: Nishimura
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D006887:Hydroxycholecalciferols / Q000008:administration & dosage*; D008297:Male; D015675:Osteocalcin / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D014807:Vitamin D / Q000378:metabolism
chemical_list: D006887:Hydroxycholecalciferols; D015675:Osteocalcin; D014807:Vitamin D; D002118:Calcium; C008088:alfacalcidol